Evidence map›Paper›PMID 40519321›Full record

ArticleMolecular therapy. Methods & clinical development2025

Self-silencing adenovirus enables precise infectious titration of recombinant adeno-associated viral vectors.

Chloé Fustinoni, Xiang Liu, Zhi Chen, Ryan Cawood, Weimin Valenti, Maria I Patrício, Weiheng Su

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chloé FustinoniOXGENE, A WuXi Advanced Therapies Company, Medawar Centre, Robert Robinson Avenue, Oxford OX4 4HG, Oxfordshire, UK.
Xiang LiuWuxi ATU Co., No. 860, Xinyang Road, Lingang, Shanghai, China.
Zhi ChenWuxi ATU Co., No. 860, Xinyang Road, Lingang, Shanghai, China.
Ryan CawoodOXGENE, A WuXi Advanced Therapies Company, Medawar Centre, Robert Robinson Avenue, Oxford OX4 4HG, Oxfordshire, UK.
Weimin ValentiWuXi Advanced Therapies, 4701 League Island Blvd, Philadelphia, PA 19112, USA.
Maria I PatrícioOXGENE, A WuXi Advanced Therapies Company, Medawar Centre, Robert Robinson Avenue, Oxford OX4 4HG, Oxfordshire, UK.
Weiheng SuOXGENE, A WuXi Advanced Therapies Company, Medawar Centre, Robert Robinson Avenue, Oxford OX4 4HG, Oxfordshire, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Robust and accurate quantification of recombinant adeno-associated virus (rAAV) vectors' infectivity is essential for pre-clinical and clinical development of AAV gene therapy programs. The industry standard method for rAAV titration is the 50% tissue culture infectious dose (TCID50) assay using HeLa-based cell lines that stably encode the

Indexed as

infectious titerrAAVTCID50TESSATREAT assay

Identifiers

PMID40519321
PMCPMC12166451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.